Rapid Disease Progression of Advanced Non-small Cell Lung Cancer Five Months after Cessation of Pembrolizumab

Medicine and Dentistry

• Pleura Effusion 100%
• Disease Exacerbation 100%
• Non Small Cell Lung Cancer 100%
• Docetaxel 100%
• Pembrolizumab 100%
• Disease 50%
• Malignant Neoplasm 50%
• Prednisolone 50%
• Diarrhea 50%
• Computer Assisted Tomography 50%
• Lung Adenocarcinoma 50%
• Immune System 50%
• Hypoxia 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Disease Exacerbation 100%
• Non Small Cell Lung Cancer 100%
• Docetaxel 100%
• Pleura Effusion 100%
• Pembrolizumab 100%
• Malignant Neoplasm 50%
• Disease 50%
• Diarrhea 50%
• Lung Adenocarcinoma 50%
• Hypoxia 50%
• Prednisolone 50%

Keyphrases

• Rapid Disease Progression 100%
• Hyperprogressive Disease 50%